Elevated Interleukin-12/23p40 Indicates Dysfunctional Heart Rate Variability in T2D
By LabMedica International staff writers Posted on 08 Feb 2022 |
Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in type 2 diabetes (T2D), accounting for approximately 50% of all deaths. Cardiovascular functions, including heart rate, heart contractility, and blood pressure, are regulated by autonomic sympathovagal balance.
Inflammation is an underlying pathogenic component in T2D, along with hyperglycemia, hyperlipidemia, and hypertension, adding to endothelial dysfunction and accelerated atherosclerosis. Systemic inflammation is assessed by serum levels of proinflammatory cytokines such as tumor necrosis factor (TNF)‐α and interleukin (IL) such as IL‐6.
Medical Scientists at the Aalborg University Hospital (Aalborg, Denmark) and their colleagues analyzed serum samples from 100 participants with type 2 diabetes who were recruited consecutively between March 2018 and August 2020. Eligible participants were ≥ 18 years old, of Northern European descent, with verified T2D for more than 1 year (HbA1c ≥ 6.5%).
Serum concentrations of angiogenetic markers [basic fibroblast growth factor (bFGF), fms related receptor tyrosine kinase(Flt)-1, phosphatidylinositol-glycan biosynthesis class F protein (PlGF), tyrosine-protein kinase(Tie)-2, vascular endothelial growth factor (VEGF)-C, VEGF-D], cytokines (IL-5, IL-7, IL-12/IL-23p40, IL-15, IL-16, IL-17A, TNF-β, VEGF-A), chemokines [Eotaxin, Eotaxin-3, interferon gamma-induced protein(IP)-10, macrophage-derived chemokine (MCP)-1, MCP-4, monocyte chemoattractant protein (MDC), macrophage inflammatory protein (MIP)-1α, MIP-1β, thymus and activation regulated chemokine (TARC)], proinflammatory cytokines [interferon(IFN)-γ, IL-2, IL-4, IL-6, IL-8, IL-10, TNF-α], and vascular injury markers [CRP, ICAM-1, soluble vascular adhesion molecule (VCAM)-1, serum amyloid A (SAA)] were analyzed using V-PLEX Neuroinflammation panel (Meso Scale Diagnostics, Rockville, MD, USA).
The investigators reported that out of 34 examined serum markers, they successfully measured six angiogenetic markers (bFGF, Flt-1, PIGF, Tie-2, VEGF-C, VEGF-D), six chemokines (Eotaxin, IP-10, MCP-1, MDC, MIP-1β, TARC), five cytokines (IL-7, IL-12/IL-23p40, IL-15, IL-16, VEGF-A), five proinflammatory markers (IL-6, IL-8, IL-10, IFN-γ, TNF-α), and four markers of vascular injury (CRP, sICAM1, sVCAM1, SAA), in more than 94% of the samples. Increased serum levels of IL-12/IL-23p40 and intercellular adhesion molecule (ICAM)-1 were associated with diminished heart rate variability measures. After all adjustments, the associations between IL-12/23p40, SDANN and VLF persisted. Additionally, serum levels of vascular endothelial growth factor (VEGF)-C were associated with response to standing.
The authors concluded that had found few but strong associations between neurocardiac function and serum markers, especially IL-12/IL-23p40, suggesting systemic changes in proinflammatory, endothelial, and lymphatic function, impacting overall cardiovascular function. The study was published on January 6 2022 in the journal Cardiovascular Diabetology.
Related Links:
Aalborg University Hospital
Meso Scale Diagnostics
Latest Immunology News
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment
- Groundbreaking Test Monitors Radiation Therapy Toxicity in Cancer Patients
- State-Of-The Art Techniques to Investigate Immune Response in Deadly Strep A Infections
- Novel Immunoassays Enable Early Diagnosis of Antiphospholipid Syndrome
- New Test Could Predict Immunotherapy Success for Broader Range Of Cancers
- Simple Blood Protein Tests Predict CAR T Outcomes for Lymphoma Patients
- Cell Sorter Chip Technology to Pave Way for Immune Profiling at POC
- Chip Monitors Cancer Cells in Blood Samples to Assess Treatment Effectiveness
- Automated Immunohematology Approaches Can Resolve Transplant Incompatibility
- AI Leverages Tumor Genetics to Predict Patient Response to Chemotherapy
- World’s First Portable, Non-Invasive WBC Monitoring Device to Eliminate Need for Blood Draw
- Predictive T-Cell Test Detects Immune Response to Viruses Even Before Antibodies Form
- Single Blood Draw to Detect Immune Cells Present Months before Flu Infection Can Predict Symptoms